Immunological effects of CD19.CAR-T cell therapy in systemic sclerosis: an extended case study
This report describes for the first time the phenotypic recovery of innate Fcγ-receptor-expressing cells in an SSc patient treated with CAR-T cells. Decreasing autoantibody levels associated with a reduced ability to form functional immune complexes, the latter appearing to contribute to pathology in SSc via activation of Fcγ receptor IIIA + cells such as NK cells.
Authors
- Michael Schmitt (ORCID: https://orcid.org/0000-0002-1579-1509)
- Maren Claus (ORCID: https://orcid.org/0000-0001-8732-0645)
- Carsten Watzl (ORCID: https://orcid.org/0000-0001-5195-0995)
- Wolfgang Merkt (ORCID: https://orcid.org/0000-0002-3108-154X)
- Philipp Kolb (ORCID: https://orcid.org/0000-0001-7935-217X)
- Hanns‐Martin Lorenz (ORCID: https://orcid.org/0000-0003-0305-0946)
- Lea Rodon
- Franca Sophie Deicher
- Merle Freitag
- Meike Ewald
Institutions
- University of Freiburg (DE)
- TU Dortmund University (DE)
- Heidelberg University (DE)
- University Medical Center Freiburg (DE)
- University Hospital Heidelberg (DE)
- Düsseldorf University Hospital (DE)
- Leibniz Research Centre for Working Environment and Human Factors (DE)
- Heinrich Heine University Düsseldorf (DE)
Publication Details
- Journal
- Arthritis Research & Therapy
- Published
- 2024-12-13
- DOI
- https://doi.org/10.1186/s13075-024-03451-1
- Citations
- 12
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 3.39
Funders
- Universitätsklinikum Heidelberg